--- title: "Alpha-Lipoic Acid: Dosing & Vendor Prices — BodyHackGuide" description: "Alpha-Lipoic Acid: dosing protocols, mechanism & side effects. Compare verified vendor prices." lang: en json-ld: | [ { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://www.bodyhackguide.co/" }, { "@type": "ListItem", "position": 2, "name": "Compounds", "item": "https://www.bodyhackguide.co/compare" }, { "@type": "ListItem", "position": 3, "name": "Alpha-Lipoic Acid" } ] }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "Alpha-Lipoic Acid", "description": "Alpha-lipoic acid (ALA), also known as thioctic acid or 1,2-dithiolane-3-pentanoic acid, is a sulfur-containing eight-carbon fatty acid derivative synthesized endogenously in mitochondria by lipoic acid synthase (LIAS). In its native biological role, ALA serves as an essential cofactor for five critical mitochondrial dehydrogenase enzyme complexes: pyruvate dehydrogenase (the gateway from glycolysis to the citric acid cycle), α-ketoglutarate dehydrogenase (a rate-limiting TCA cycle enzyme), branched-chain α-ketoacid dehydrogenase (metabolizing leucine, isoleucine, and valine), 2-oxoadipate dehydrogenase, and the glycine cleavage system. In all these roles, ALA is covalently attached via an amide bond to a specific lysine residue on a dihydrolipoyl-binding subunit, where it serves as a \"swinging arm\" that shuttles acyl groups and reducing equivalents between catalytic sites. Loss of lipoic acid synthase function produces a catastrophic inherited metabolic disease; no human can live without endogenous ALA. When taken as a dietary supplement, exogenous ALA does not meaningfully replace or supplement the endogenous enzyme-bound lipoic acid — the biosynthetic pathway is tightly compartmentalized, and supplemental ALA does not become covalently attached to dehydrogenase complexes. Instead, supplemental ALA exerts its biological effects through a different mechanism: it exists transiently in the plasma and cytoplasm as a free molecule and redox couple with dihydrolipoic acid (DHLA), where it functions as one of the most versatile antioxidants known in human biology. Unlike most antioxidants that are restricted to either water-soluble or lipid-soluble compartments, ALA and DHLA are amphipathic — they function effectively in both aqueous cytoplasm and lipid membranes, enabling them to quench free radicals across the cellular landscape. Lester Packer's seminal reviewdesignated ALA a \"universal antioxidant\" in recognition of this dual-phase activity and its capacity to regenerate oxidized forms of vitamin C, vitamin E, glutathione, and CoQ10 back to their active reduced states. This regenerative function makes ALA a keystone in the network of cellular antioxidant recycling. The strongest clinical evidence for supplemental ALA is in diabetic neuropathy, where Germany has licensed ALA at 600 mg/day since the 1960s based on the ALADIN series of randomized trials (PMIDs 7589950, 10391387), the SYDNEY 2 trial, and the four-year NATHAN 1 study. These trials established that 600 mg/day of oral ALA meaningfully reduces neuropathic symptoms (pain, burning, paresthesias, numbness) and improves nerve conduction in patients with type 1 and type 2 diabetes. The mechanism appears to combine direct antioxidant protection of vulnerable peripheral nerves, improved microvascular perfusion via nitric oxide enhancement, modulation of polyol and hexosamine pathway damage from hyperglycemia, and genuine insulin-sensitizing effects on glucose disposal. Beyond neuropathy, ALA has been investigated for insulin resistance and metabolic syndrome, non-alcoholic fatty liver disease, mitochondrial disorders, stroke recovery, burning mouth syndrome, and weight management — with evidence quality and effect sizes varying widely. ALA also has a small but important role in heavy metal chelation, particularly mercury and arsenic. The dithiol structure of dihydrolipoic acid (DHLA, the reduced form of ALA) can bind soft metal cations. Andrew Cutler's protocols for mercury detoxification popularized ALA as a chelator among biohackers; while the mainstream chelation medical community uses DMSA or DMPS as first-line agents, ALA has an established but more peripheral role. The protocol logic depends on careful dosing schedules that respect the short plasma half-life (30-60 minutes) of ALA to avoid mobilizing mercury from stable deposits faster than the body can excrete it. For BodyHackGuide readers, ALA represents an antioxidant with legitimate clinical evidence in specific indications, meaningful insulin-sensitizing effects, and a niche role in mitochondrial support — but it is not a \"clean\" supplement in the sense that vitamin D or magnesium are. ALA requires attention to isomer selection (R-ALA is the natural form with better bioavailability; S-ALA is the synthetic enantiomer present in racemic commercial products), absorption tuning (empty stomach is important), biotin competition (chronic high-dose ALA can induce functional biotin deficiency), hypoglycemia risk in diabetics taking insulin or sulfonylureas, and the unfortunate reality that most over-the-counter ALA products are racemic rather than pure R-ALA. This page covers the biochemistry, the diabetic neuropathy evidence, the chelation debate, stacking with glutathione-system and mitochondrial nutrients, and practical dosing considerations.", "lastReviewed": "2026-05-04T11:34:38.758+00:00", "url": "https://www.bodyhackguide.co/compound/alpha-lipoic-acid", "author": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "reviewedBy": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "publisher": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" }, "mainContentOfPage": { "@type": "WebPageElement", "cssSelector": "main" }, "about": { "@type": "Drug", "name": "Alpha-Lipoic Acid", "alternateName": [ "ALA", "α-Lipoic acid", "Alpha lipoic acid", "Thioctic acid", "R-Lipoic acid", "R-ALA", "R-(+)-Lipoic acid", "S-Lipoic acid", "Na-R-ALA", "Sodium R-lipoate", "Lipoate", "1,2-Dithiolane-3-pentanoic acid" ], "description": "Alpha-lipoic acid (ALA), also known as thioctic acid or 1,2-dithiolane-3-pentanoic acid, is a sulfur-containing eight-carbon fatty acid derivative synthesized endogenously in mitochondria by lipoic acid synthase (LIAS). In its native biological role, ALA serves as an essential cofactor for five critical mitochondrial dehydrogenase enzyme complexes: pyruvate dehydrogenase (the gateway from glycolysis to the citric acid cycle), α-ketoglutarate dehydrogenase (a rate-limiting TCA cycle enzyme), branched-chain α-ketoacid dehydrogenase (metabolizing leucine, isoleucine, and valine), 2-oxoadipate dehydrogenase, and the glycine cleavage system. In all these roles, ALA is covalently attached via an amide bond to a specific lysine residue on a dihydrolipoyl-binding subunit, where it serves as a \"swinging arm\" that shuttles acyl groups and reducing equivalents between catalytic sites. Loss of lipoic acid synthase function produces a catastrophic inherited metabolic disease; no human can live without endogenous ALA. When taken as a dietary supplement, exogenous ALA does not meaningfully replace or supplement the endogenous enzyme-bound lipoic acid — the biosynthetic pathway is tightly compartmentalized, and supplemental ALA does not become covalently attached to dehydrogenase complexes. Instead, supplemental ALA exerts its biological effects through a different mechanism: it exists transiently in the plasma and cytoplasm as a free molecule and redox couple with dihydrolipoic acid (DHLA), where it functions as one of the most versatile antioxidants known in human biology. Unlike most antioxidants that are restricted to either water-soluble or lipid-soluble compartments, ALA and DHLA are amphipathic — they function effectively in both aqueous cytoplasm and lipid membranes, enabling them to quench free radicals across the cellular landscape. Lester Packer's seminal reviewdesignated ALA a \"universal antioxidant\" in recognition of this dual-phase activity and its capacity to regenerate oxidized forms of vitamin C, vitamin E, glutathione, and CoQ10 back to their active reduced states. This regenerative function makes ALA a keystone in the network of cellular antioxidant recycling. The strongest clinical evidence for supplemental ALA is in diabetic neuropathy, where Germany has licensed ALA at 600 mg/day since the 1960s based on the ALADIN series of randomized trials (PMIDs 7589950, 10391387), the SYDNEY 2 trial, and the four-year NATHAN 1 study. These trials established that 600 mg/day of oral ALA meaningfully reduces neuropathic symptoms (pain, burning, paresthesias, numbness) and improves nerve conduction in patients with type 1 and type 2 diabetes. The mechanism appears to combine direct antioxidant protection of vulnerable peripheral nerves, improved microvascular perfusion via nitric oxide enhancement, modulation of polyol and hexosamine pathway damage from hyperglycemia, and genuine insulin-sensitizing effects on glucose disposal. Beyond neuropathy, ALA has been investigated for insulin resistance and metabolic syndrome, non-alcoholic fatty liver disease, mitochondrial disorders, stroke recovery, burning mouth syndrome, and weight management — with evidence quality and effect sizes varying widely. ALA also has a small but important role in heavy metal chelation, particularly mercury and arsenic. The dithiol structure of dihydrolipoic acid (DHLA, the reduced form of ALA) can bind soft metal cations. Andrew Cutler's protocols for mercury detoxification popularized ALA as a chelator among biohackers; while the mainstream chelation medical community uses DMSA or DMPS as first-line agents, ALA has an established but more peripheral role. The protocol logic depends on careful dosing schedules that respect the short plasma half-life (30-60 minutes) of ALA to avoid mobilizing mercury from stable deposits faster than the body can excrete it. For BodyHackGuide readers, ALA represents an antioxidant with legitimate clinical evidence in specific indications, meaningful insulin-sensitizing effects, and a niche role in mitochondrial support — but it is not a \"clean\" supplement in the sense that vitamin D or magnesium are. ALA requires attention to isomer selection (R-ALA is the natural form with better bioavailability; S-ALA is the synthetic enantiomer present in racemic commercial products), absorption tuning (empty stomach is important), biotin competition (chronic high-dose ALA can induce functional biotin deficiency), hypoglycemia risk in diabetics taking insulin or sulfonylureas, and the unfortunate reality that most over-the-counter ALA products are racemic rather than pure R-ALA. This page covers the biochemistry, the diabetic neuropathy evidence, the chelation debate, stacking with glutathione-system and mitochondrial nutrients, and practical dosing considerations.", "activeIngredient": "Alpha-Lipoic Acid", "mechanismOfAction": "Alpha-lipoic acid has two distinct biological identities. The endogenous pool — synthesized by mitochondrial lipoic acid synthase (LIAS) and covalently attached to specific lysine residues on dehydrogenase complex subunits — is catalytically essential and not meaningfully affected by dietary or supplemental ALA. The supplemental pool — absorbed from the gut, transiting plasma and tissues, cycling between oxidized ALA and reduced dihydrolipoic acid (DHLA), and eventually metabolized and excreted — is what produces the clinical effects of ALA supplementation. Understanding this distinction resolves most of the confusion around ALA pharmacology. ENDOGENOUS ALA AS ENZYME COFACTOR. In mitochondria, lipoic acid is synthesized de novo from octanoic acid (an 8-carbon fatty acid) by LIAS, which inserts two sulfur atoms between C6 and C8 to form the characteristic dithiolane ring. The resulting lipoyl group is transferred to specific lysine residues on the E2 (dihydrolipoyl acyltransferase) subunits of the dehydrogenase complexes — pyruvate dehydrogenase, α-ketoglutarate dehydrogenase, branched-chain ketoacid dehydrogenase, 2-oxoadipate dehydrogenase, and the glycine cleavage system H-protein. In catalysis, the lipoyl arm swings between the E1 (decarboxylase), E2 (acyltransferase), and E3 (dihydrolipoyl dehydrogenase) active sites, receiving an acyl group from a thiamine-bound intermediate, transferring it to CoA, and delivering reducing equivalents to FAD on E3. This mechanism is exquisitely conserved from bacteria to humans and is the reason lipoic acid is essential for aerobic energy metabolism and amino acid catabolism. Supplemental ALA does not supply enzyme-bound lipoic acid because the biosynthetic pathway is compartmentalized and the attachment to E2 subunits occurs co-translationally or post-translationally from endogenous synthesis, not from dietary uptake. REDOX CYCLING OF FREE ALA/DHLA. Supplemental ALA enters cells, where it is reduced by NADH or NADPH-dependent enzymes (mitochondrial dihydrolipoamide dehydrogenase, cytosolic thioredoxin reductase, glutathione reductase) to dihydrolipoic acid. The ALA/DHLA couple has a redox potential of approximately -320 mV, making DHLA one of the most powerful biological reductants — more reducing than glutathione (GSSG/2GSH = -240 mV) and capable of reducing most oxidized biological thiols. Because both ALA and DHLA are amphipathic, they partition into both aqueous and lipid environments and can quench oxidants across the cellular landscape. DHLA directly scavenges hydroxyl radicals, hypochlorous acid, peroxyl radicals, peroxynitrite, and singlet oxygen. Both ALA and DHLA chelate transition metals (particularly Cu2+, Fe2+, Mn2+, Zn2+) that catalyze Fenton-type radical generation. REGENERATION OF OTHER ANTIOXIDANTS. Packer's \"universal antioxidant\" framing rests on DHLA's capacity to regenerate oxidized forms of other antioxidants: DHLA reduces dehydroascorbate (oxidized vitamin C) back to ascorbate, allowing vitamin C to re-engage in reducing chemistry; DHLA reduces glutathione disulfide (GSSG) to glutathione (GSH); DHLA reduces tocopheroxyl radical (oxidized vitamin E) back to α-tocopherol through an indirect path via ascorbate or directly; DHLA can reduce ubiquinone (oxidized CoQ10) to ubiquinol. This interconnected web allows cells to maintain reduced antioxidant pools under oxidative stress in ways that individual antioxidants alone cannot. INSULIN SENSITIVITY AND GLUCOSE DISPOSAL. ALA has well-documented insulin-sensitizing effects that are distinct from its antioxidant activity. Intravenous ALA 600 mg produces acute improvements in insulin-mediated glucose disposal in type 2 diabetic patients (Jacob et al), with effect sizes comparable to low-dose insulin-sensitizers. The mechanism involves increased GLUT4 translocation to the plasma membrane of muscle and adipose cells, activation of AMP-activated protein kinase (AMPK) in liver and muscle, modulation of tyrosine phosphorylation of the insulin receptor and IRS-1, and improved endothelial function with enhanced nitric oxide-mediated vasodilation. Oral ALA at 600-1800 mg/day produces more modest but measurable improvements in HOMA-IR, fasting glucose, and HbA1c in metabolic syndrome and type 2 diabetes, though effect sizes are smaller than metformin or GLP-1 agonists. DIABETIC NEUROPATHY MECHANISMS. The neuropathy protection observed in ALADIN and NATHAN trials reflects multiple convergent mechanisms. Hyperglycemia in diabetes drives pathological glucose metabolism through four damage pathways: increased polyol pathway flux (sorbitol/fructose accumulation in neural tissue), increased advanced glycation end-product formation, activation of protein kinase C isoforms, and increased hexosamine pathway flux. All four pathways generate mitochondrial superoxide as a common final mediator. ALA intercepts mitochondrial ROS, protects polyunsaturated fatty acids in nerve membranes from lipid peroxidation, and improves endoneurial blood flow through enhanced nitric oxide-mediated vasodilation. Clinically, this translates to reduced neuropathic pain, improved vibration sensitivity, and preserved nerve conduction velocity — effects that accumulate over months of therapy. R vs S ENANTIOMERS. The natural enantiomer is R-(+)-lipoic acid; S-(−)-lipoic acid is present only in chemically synthesized material. Commercial racemic ALA is a 50:50 mixture. Biochemically, R-ALA is the form recognized by LIAS and by the enzymes that reduce ALA to DHLA; S-ALA is poorly metabolized and may even competitively inhibit R-ALA pharmacology in some systems. Pharmacokinetic studies show that oral R-ALA has approximately 40% higher peak plasma concentrations than the racemic mixture at equivalent total doses (Hermann et al). Stabilized sodium R-lipoate formulations (Na-R-ALA) further improve bioavailability by 10-30% over free R-ALA due to better solubility and less pre-systemic degradation. For most indications, R-ALA or Na-R-ALA at lower doses (200-600 mg) achieves equivalent or superior effects to racemic ALA at higher doses (600-1200 mg), but the price differential is substantial. HEAVY METAL CHELATION. DHLA contains two thiol groups at positions 6 and 8 of the pentanoic acid backbone, oriented such that they can coordinate soft Lewis acid metal cations. Mercury (Hg2+ and methylmercury), arsenic (As3+), lead (Pb2+), and cadmium (Cd2+) form stable complexes with DHLA, and the resulting chelate is more hydrophilic than the free metal, promoting renal excretion. ALA's small size (molecular weight 206) allows it to cross cell membranes and the blood-brain barrier, distinguishing it from larger chelators like DMSA or EDTA that cannot access intracellular or CNS mercury pools. This tissue penetration is the basis for Cutler's protocol for methylmercury mobilization. However, the short plasma half-life of ALA (30-60 minutes after oral dosing) means that single doses produce transient chelation followed by redistribution — which is why Cutler protocols specify dosing every 3-4 hours around the clock during active chelation rounds, a substantial adherence burden. PHARMACOKINETICS. Oral ALA is absorbed via monocarboxylate transporters in the small intestine with bioavailability of 20-40% for racemic ALA and 40-60% for R-ALA; taking on empty stomach and separately from high-carbohydrate meals improves absorption significantly. Peak plasma concentrations occur 30-60 minutes post-dose. The half-life is 30-60 minutes; ALA undergoes extensive first-pass hepatic metabolism via β-oxidation of the pentanoic acid tail, S-methylation, and oxidation, producing a family of metabolites including bisnorlipoic acid, tetranorlipoic acid, and their β-oxidized sulfur-oxidized derivatives. The short half-life means that sustained plasma exposure requires either frequent dosing or sustained-release formulations; most commercial products are immediate-release and produce brief peak exposures followed by rapid clearance. Despite this, the biological effects of ALA (particularly on insulin sensitivity and neuropathy) accumulate over weeks of dosing, suggesting that either tissue accumulation or downstream signaling changes mediate the sustained effects rather than moment-to-moment plasma concentration. BIOTIN COMPETITION. ALA and biotin share structural similarities (both contain sulfur-heterocyclic rings fused to a pentanoic acid-like tail) and use the same intestinal uptake transporter (sodium-dependent multivitamin transporter, SMVT). High-dose ALA competitively inhibits biotin absorption and can induce functional biotin deficiency with chronic use at doses ≥600 mg/day (Zempleni et al). Since biotin is required for four carboxylase enzymes (acetyl-CoA carboxylase, pyruvate carboxylase, propionyl-CoA carboxylase, β-methylcrotonyl-CoA carboxylase), biotin deficiency can produce its own metabolic consequences. Co-supplementation with biotin 2-5 mg/day is standard for chronic high-dose ALA protocols.", "legalStatus": "Not approved for human use — research chemical", "warning": "For research purposes only. Not for human consumption." } }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Does alpha-lipoic acid actually help with diabetic neuropathy, or is this just marketing?", "acceptedAnswer": { "@type": "Answer", "text": "The diabetic neuropathy evidence for ALA is among the strongest evidence bases for any supplement. Multiple randomized controlled trials — ALADIN (PMID 7589950), ALADIN III (PMID 10391387), SYDNEY 2 (PMID 17140036), and the four-year NATHAN 1 (PMID 21953615) — consistently demonstrate that 600 mg/day of oral ALA meaningfully reduces neuropathic symptoms (pain, burning, paresthesias, numbness) and improves nerve conduction in type 1 and type 2 diabetics. The effect sizes are clinically meaningful and comparable to pharmaceutical options like duloxetine or pregabalin. Germany has licensed ALA at 600 mg/day as a prescription medication for diabetic polyneuropathy since the 1960s based on this evidence. Expected timeline: symptom improvement over 3-5 weeks of oral therapy, with greater improvements if started with IV loading at a functional medicine clinic. This is one of the few supplements where the evidence base rivals or exceeds pharmaceutical alternatives, and where clinical practice in one major country has formally recognized the benefit." } }, { "@type": "Question", "name": "Is R-ALA really better than racemic, or is that just expensive marketing?", "acceptedAnswer": { "@type": "Answer", "text": "R-ALA is biologically superior — it''s the natural enantiomer used by human enzymes, while the synthetic S-ALA in racemic mixtures is poorly metabolized and may even competitively inhibit R-ALA pharmacology. Pharmacokinetic studies (Hermann PMID 17024766) show R-ALA has approximately 40% higher peak plasma concentrations and 2-3x higher AUC than racemic at equivalent total doses. In practice, 300 mg R-ALA approximates 600 mg racemic. Whether this is worth the roughly 2-3x price premium depends on context. For general antioxidant support, racemic at higher doses is fine and cost-effective. For clinical indications (diabetic neuropathy, insulin resistance) where the trial evidence used racemic, matching the trial dose (600 mg racemic) is reasonable. For users with GI intolerance to high-dose racemic, R-ALA at lower doses achieves the same effects with less GI burden. Stabilized sodium R-lipoate (Na-R-ALA) further improves bioavailability and is worth the premium for serious users. Beware that some products marketed as \"R-ALA\" are racemic — purchase from reputable suppliers with third-party verification." } }, { "@type": "Question", "name": "Can ALA really help me lose weight?", "acceptedAnswer": { "@type": "Answer", "text": "The weight-loss effect of ALA is real but modest. Meta-analyses (Namazi PMID 28456476; Kucukgoncu PMID 27702795) found that ALA at 600-1800 mg/day produces approximately 1-2 kg additional weight loss over placebo during 8-20 week trials. The mechanism involves AMPK activation in the hypothalamus (reduced appetite) and peripheral tissues (enhanced fatty acid oxidation), plus improved insulin sensitivity. This is a meaningful but small effect — ALA is not a primary weight-loss intervention, comparable perhaps to modest dietary changes rather than medications like GLP-1 agonists. ALA may be a reasonable adjunct for users pursuing comprehensive lifestyle-based weight management, particularly those with insulin resistance or metabolic syndrome where ALA''s other benefits compound. Do not expect dramatic results from ALA monotherapy for obesity." } }, { "@type": "Question", "name": "Do I need to worry about hypoglycemia from ALA?", "acceptedAnswer": { "@type": "Answer", "text": "Yes, if you''re diabetic on insulin, sulfonylureas, or meglitinides. ALA''s insulin-sensitizing effects can precipitate symptomatic hypoglycemia, particularly during the first 2-4 weeks of initiation or dose increase. Check blood glucose more frequently during this window, and anticipate that insulin or sulfonylurea doses may need reduction (often 10-20%). Discuss ALA with your prescribing clinician before starting if on these medications. For diabetics on metformin alone, hypoglycemia risk is low because metformin itself rarely causes hypoglycemia. For non-diabetics, clinically significant hypoglycemia from ALA is uncommon but has been reported, especially with high doses on empty stomach combined with low-carbohydrate eating or fasting. If you experience symptoms of hypoglycemia (shakiness, sweating, confusion, palpitations) after ALA, check blood glucose if possible and eat some carbohydrate. Persistent issues warrant reducing ALA dose or discontinuation." } }, { "@type": "Question", "name": "Should I take ALA with food or on empty stomach?", "acceptedAnswer": { "@type": "Answer", "text": "Empty stomach — 30-60 minutes before a meal or 2 hours after — produces approximately 30-50% higher plasma concentrations than taking with food, particularly carbohydrate-rich meals. Take your ALA in the morning fasted, or pre-workout, or well before lunch. If empty stomach causes GI upset (nausea, heartburn), a small amount of protein (e.g., a handful of nuts, a small piece of cheese) represents a reasonable compromise that preserves most of the absorption advantage. Avoid taking with large mixed meals. Some commercial products use time-release technology or liposomal delivery to reduce GI irritation, but this may also reduce peak plasma exposure and thus reduce insulin-sensitivity effects — simple immediate-release with empty-stomach dosing is the best balance for most users. If you''re on levothyroxine for thyroid, take it morning fasted and separate your ALA by at least 4 hours (typically ALA with lunch or late afternoon)." } }, { "@type": "Question", "name": "Is ALA safe long-term?", "acceptedAnswer": { "@type": "Answer", "text": "Yes, generally. The longest controlled safety data comes from NATHAN 1, a 4-year trial of 600 mg/day in diabetic polyneuropathy patients with no major safety signals (PMID 21953615). German clinical practice has used 300-600 mg/day for neuropathy for decades without emerging safety concerns. Chronic use at standard doses (300-600 mg/day) appears very safe. The main considerations for long-term users are: (1) biotin replacement — chronic high-dose ALA competes with biotin absorption at the SMVT transporter, producing functional biotin deficiency over months; add biotin 2-5 mg/day to prevent this; (2) occasional monitoring of liver enzymes, glucose, and thyroid function if on chronic high-dose; (3) awareness of insulin autoimmune syndrome risk in Asian populations; (4) appropriate adjustments for concurrent diabetes medications. At standard doses with these precautions, ALA is among the safer supplements for indefinite use. Very high doses (≥1800 mg/day) for extended periods have less long-term data and should be reserved for specific indications with medical oversight." } }, { "@type": "Question", "name": "Does ALA actually chelate mercury and other heavy metals?", "acceptedAnswer": { "@type": "Answer", "text": "Biochemically, yes — dihydrolipoic acid (DHLA, the reduced form of ALA) has two thiol groups in an orientation that forms stable complexes with mercury, arsenic, lead, and cadmium, and ALA''s small size allows intracellular and CNS penetration that larger chelators like DMSA can''t achieve. Whether it works clinically depends heavily on the protocol. The Andrew Cutler protocols specify dosing every 3-4 hours around the clock during active \"rounds\" because ALA''s short half-life (30-60 minutes) means that single or twice-daily dosing can mobilize mercury from tissues faster than the body excretes it, potentially causing redistribution to sensitive tissues including the brain. For documented heavy metal toxicity, mainstream occupational and toxicology medicine still prefers DMSA or DMPS as first-line chelators — they have more controlled clinical trial evidence and simpler dosing. ALA has a legitimate role in integrative chelation protocols but should be pursued with a clinician experienced in heavy metal therapy, not as a DIY project. For users concerned about mercury from dental amalgams or fish consumption without documented toxicity, ALA''s general antioxidant support is reasonable and low-risk, while aggressive chelation protocols require careful consideration and supervision." } }, { "@type": "Question", "name": "Will ALA interfere with my chemotherapy?", "acceptedAnswer": { "@type": "Answer", "text": "This is a genuinely unresolved question. The theoretical concern is that antioxidants may reduce the efficacy of chemotherapy agents (cisplatin, carboplatin, doxorubicin, taxanes) and radiation therapy that work through oxidative damage to cancer cells. Clinical evidence is mixed — some studies suggest ALA selectively protects healthy tissue (reducing chemotherapy-induced peripheral neuropathy) without impairing tumor response, while others raise concerns about reduced treatment efficacy. The safe default for patients on active chemotherapy or radiation is to avoid ALA and other high-dose antioxidants during treatment cycles, or to discuss with the treating oncologist before starting. Post-treatment use for established chemotherapy-induced peripheral neuropathy is much better supported and lower-risk. If your oncologist is unfamiliar with ALA specifically, asking them to review the mixed literature on antioxidants during chemotherapy is reasonable — the answer often depends on the specific drug, cancer type, and treatment goals." } }, { "@type": "Question", "name": "Can ALA help with insulin resistance or metabolic syndrome even if I''m not diabetic?", "acceptedAnswer": { "@type": "Answer", "text": "Yes, to a modest degree. Meta-analyses show that ALA 600-1800 mg/day produces measurable but modest improvements in HOMA-IR (insulin resistance index), fasting glucose, HbA1c, and triglycerides in metabolic syndrome and pre-diabetes (Akbari PMID 29361170). Effect sizes are smaller than metformin or GLP-1 agonists but real. For non-diabetics pursuing metabolic optimization, ALA is a reasonable component of a comprehensive approach that also emphasizes exercise, diet, weight management, magnesium, and other insulin-supportive nutrients. Expect modest improvements in HOMA-IR over 3-6 months. If pre-diabetic with significant insulin resistance, consider combining ALA with berberine 500 mg 2-3x daily and metformin if prescribed by your clinician for additive AMPK activation. Don''t expect ALA alone to resolve serious metabolic dysfunction without concurrent lifestyle intervention." } }, { "@type": "Question", "name": "Why do I need to take biotin with ALA?", "acceptedAnswer": { "@type": "Answer", "text": "Because ALA and biotin share the same intestinal uptake transporter (sodium-dependent multivitamin transporter, SMVT) and have similar structural features. At doses ≥600 mg/day for more than a few months, ALA competitively inhibits biotin absorption and can induce functional biotin deficiency (Zempleni PMID 19348577). Biotin is required for four critical carboxylase enzymes in fatty acid, branched-chain amino acid, and odd-chain fatty acid metabolism, and deficiency symptoms include hair thinning, brittle nails, dermatitis, muscle pain, and in severe cases neurological effects. The solution is simple and cheap: add biotin 2-5 mg/day when taking chronic ALA ≥600 mg/day. Many commercial ALA products include biotin for this reason — check the label. Note that high-dose biotin can interfere with several laboratory immunoassays (thyroid function, cardiac troponin, hormone tests), so pause biotin for 48-72 hours before testing if your labs will be affected. For chronic ALA users not taking biotin, look for subtle signs of deficiency (hair and nail changes, skin issues) and add biotin empirically if they appear." } } ] }, { "@context": "https://schema.org", "@type": "Organization", "@id": "https://www.bodyhackguide.co#organization", "name": "BodyHackGuide", "alternateName": "BHG", "url": "https://www.bodyhackguide.co", "logo": { "@type": "ImageObject", "url": "https://www.bodyhackguide.co/logo.png", "width": 512, "height": 512 }, "description": "Evidence-based research reference for peptides and nootropics. 124+ compound profiles, interactive dosing calculators, real-time vendor pricing, and trust-scored vendor reviews scored on a public, reproducible methodology applied to every vendor. BodyHackGuide and BHG Labs share common ownership, and we earn a commission on purchases through our links.", "foundingDate": "2024", "founder": { "@id": "https://www.bodyhackguide.co/about#person" }, "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher", "https://discord.gg/Mhq5UdRYBA" ], "knowsAbout": [ "Peptide research", "Nootropic research", "Biohacking", "Compound dosing", "Vendor transparency" ], "publishingPrinciples": "https://www.bodyhackguide.co/editorial-standards", "ethicsPolicy": "https://www.bodyhackguide.co/editorial-standards", "diversityPolicy": "https://www.bodyhackguide.co/editorial-standards" }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "Alpha-Lipoic Acid", "description": "Alpha-lipoic acid (ALA), also known as thioctic acid or 1,2-dithiolane-3-pentanoic acid, is a sulfur-containing eight-carbon fatty acid derivative synthesized endogenously in mitochondria by lipoic acid synthase (LIAS). In its native biological role, ALA serves as an essential cofactor for five critical mitochondrial dehydrogenase enzyme complexes: pyruvate dehydrogenase (the gateway from glycolysis to the citric acid cycle), α-ketoglutarate dehydrogenase (a rate-limiting TCA cycle enzyme), branched-chain α-ketoacid dehydrogenase (metabolizing leucine, isoleucine, and valine), 2-oxoadipate dehydrogenase, and the glycine cleavage system. In all these roles, ALA is covalently attached via an amide bond to a specific lysine residue on a dihydrolipoyl-binding subunit, where it serves as a \"swinging arm\" that shuttles acyl groups and reducing equivalents between catalytic sites. Loss of lipoic acid synthase function produces a catastrophic inherited metabolic disease; no human can live without endogenous ALA. When taken as a dietary supplement, exogenous ALA does not meaningfully replace or supplement the endogenous enzyme-bound lipoic acid — the biosynthetic pathway is tightly compartmentalized, and supplemental ALA does not become covalently attached to dehydrogenase complexes. Instead, supplemental ALA exerts its biological effects through a different mechanism: it exists transiently in the plasma and cytoplasm as a free molecule and redox couple with dihydrolipoic acid (DHLA), where it functions as one of the most versatile antioxidants known in human biology. Unlike most antioxidants that are restricted to either water-soluble or lipid-soluble compartments, ALA and DHLA are amphipathic — they function effectively in both aqueous cytoplasm and lipid membranes, enabling them to quench free radicals across the cellular landscape. Lester Packer's seminal reviewdesignated ALA a \"universal antioxidant\" in recognition of this dual-phase activity and its capacity to regenerate oxidized forms of vitamin C, vitamin E, glutathione, and CoQ10 back to their active reduced states. This regenerative function makes ALA a keystone in the network of cellular antioxidant recycling. The strongest clinical evidence for supplemental ALA is in diabetic neuropathy, where Germany has licensed ALA at 600 mg/day since the 1960s based on the ALADIN series of randomized trials (PMIDs 7589950, 10391387), the SYDNEY 2 trial, and the four-year NATHAN 1 study. These trials established that 600 mg/day of oral ALA meaningfully reduces neuropathic symptoms (pain, burning, paresthesias, numbness) and improves nerve conduction in patients with type 1 and type 2 diabetes. The mechanism appears to combine direct antioxidant protection of vulnerable peripheral nerves, improved microvascular perfusion via nitric oxide enhancement, modulation of polyol and hexosamine pathway damage from hyperglycemia, and genuine insulin-sensitizing effects on glucose disposal. Beyond neuropathy, ALA has been investigated for insulin resistance and metabolic syndrome, non-alcoholic fatty liver disease, mitochondrial disorders, stroke recovery, burning mouth syndrome, and weight management — with evidence quality and effect sizes varying widely. ALA also has a small but important role in heavy metal chelation, particularly mercury and arsenic. The dithiol structure of dihydrolipoic acid (DHLA, the reduced form of ALA) can bind soft metal cations. Andrew Cutler's protocols for mercury detoxification popularized ALA as a chelator among biohackers; while the mainstream chelation medical community uses DMSA or DMPS as first-line agents, ALA has an established but more peripheral role. The protocol logic depends on careful dosing schedules that respect the short plasma half-life (30-60 minutes) of ALA to avoid mobilizing mercury from stable deposits faster than the body can excrete it. For BodyHackGuide readers, ALA represents an antioxidant with legitimate clinical evidence in specific indications, meaningful insulin-sensitizing effects, and a niche role in mitochondrial support — but it is not a \"clean\" supplement in the sense that vitamin D or magnesium are. ALA requires attention to isomer selection (R-ALA is the natural form with better bioavailability; S-ALA is the synthetic enantiomer present in racemic commercial products), absorption tuning (empty stomach is important), biotin competition (chronic high-dose ALA can induce functional biotin deficiency), hypoglycemia risk in diabetics taking insulin or sulfonylureas, and the unfortunate reality that most over-the-counter ALA products are racemic rather than pure R-ALA. This page covers the biochemistry, the diabetic neuropathy evidence, the chelation debate, stacking with glutathione-system and mitochondrial nutrients, and practical dosing considerations.", "lastReviewed": "2026-05-04T11:34:38.758+00:00", "url": "https://www.bodyhackguide.co/compound/alpha-lipoic-acid", "author": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "reviewedBy": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "publisher": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" }, "mainContentOfPage": { "@type": "WebPageElement", "cssSelector": "main" }, "about": { "@type": "Drug", "name": "Alpha-Lipoic Acid", "alternateName": [ "ALA", "α-Lipoic acid", "Alpha lipoic acid", "Thioctic acid", "R-Lipoic acid", "R-ALA", "R-(+)-Lipoic acid", "S-Lipoic acid", "Na-R-ALA", "Sodium R-lipoate", "Lipoate", "1,2-Dithiolane-3-pentanoic acid" ], "description": "Alpha-lipoic acid (ALA), also known as thioctic acid or 1,2-dithiolane-3-pentanoic acid, is a sulfur-containing eight-carbon fatty acid derivative synthesized endogenously in mitochondria by lipoic acid synthase (LIAS). In its native biological role, ALA serves as an essential cofactor for five critical mitochondrial dehydrogenase enzyme complexes: pyruvate dehydrogenase (the gateway from glycolysis to the citric acid cycle), α-ketoglutarate dehydrogenase (a rate-limiting TCA cycle enzyme), branched-chain α-ketoacid dehydrogenase (metabolizing leucine, isoleucine, and valine), 2-oxoadipate dehydrogenase, and the glycine cleavage system. In all these roles, ALA is covalently attached via an amide bond to a specific lysine residue on a dihydrolipoyl-binding subunit, where it serves as a \"swinging arm\" that shuttles acyl groups and reducing equivalents between catalytic sites. Loss of lipoic acid synthase function produces a catastrophic inherited metabolic disease; no human can live without endogenous ALA. When taken as a dietary supplement, exogenous ALA does not meaningfully replace or supplement the endogenous enzyme-bound lipoic acid — the biosynthetic pathway is tightly compartmentalized, and supplemental ALA does not become covalently attached to dehydrogenase complexes. Instead, supplemental ALA exerts its biological effects through a different mechanism: it exists transiently in the plasma and cytoplasm as a free molecule and redox couple with dihydrolipoic acid (DHLA), where it functions as one of the most versatile antioxidants known in human biology. Unlike most antioxidants that are restricted to either water-soluble or lipid-soluble compartments, ALA and DHLA are amphipathic — they function effectively in both aqueous cytoplasm and lipid membranes, enabling them to quench free radicals across the cellular landscape. Lester Packer's seminal reviewdesignated ALA a \"universal antioxidant\" in recognition of this dual-phase activity and its capacity to regenerate oxidized forms of vitamin C, vitamin E, glutathione, and CoQ10 back to their active reduced states. This regenerative function makes ALA a keystone in the network of cellular antioxidant recycling. The strongest clinical evidence for supplemental ALA is in diabetic neuropathy, where Germany has licensed ALA at 600 mg/day since the 1960s based on the ALADIN series of randomized trials (PMIDs 7589950, 10391387), the SYDNEY 2 trial, and the four-year NATHAN 1 study. These trials established that 600 mg/day of oral ALA meaningfully reduces neuropathic symptoms (pain, burning, paresthesias, numbness) and improves nerve conduction in patients with type 1 and type 2 diabetes. The mechanism appears to combine direct antioxidant protection of vulnerable peripheral nerves, improved microvascular perfusion via nitric oxide enhancement, modulation of polyol and hexosamine pathway damage from hyperglycemia, and genuine insulin-sensitizing effects on glucose disposal. Beyond neuropathy, ALA has been investigated for insulin resistance and metabolic syndrome, non-alcoholic fatty liver disease, mitochondrial disorders, stroke recovery, burning mouth syndrome, and weight management — with evidence quality and effect sizes varying widely. ALA also has a small but important role in heavy metal chelation, particularly mercury and arsenic. The dithiol structure of dihydrolipoic acid (DHLA, the reduced form of ALA) can bind soft metal cations. Andrew Cutler's protocols for mercury detoxification popularized ALA as a chelator among biohackers; while the mainstream chelation medical community uses DMSA or DMPS as first-line agents, ALA has an established but more peripheral role. The protocol logic depends on careful dosing schedules that respect the short plasma half-life (30-60 minutes) of ALA to avoid mobilizing mercury from stable deposits faster than the body can excrete it. For BodyHackGuide readers, ALA represents an antioxidant with legitimate clinical evidence in specific indications, meaningful insulin-sensitizing effects, and a niche role in mitochondrial support — but it is not a \"clean\" supplement in the sense that vitamin D or magnesium are. ALA requires attention to isomer selection (R-ALA is the natural form with better bioavailability; S-ALA is the synthetic enantiomer present in racemic commercial products), absorption tuning (empty stomach is important), biotin competition (chronic high-dose ALA can induce functional biotin deficiency), hypoglycemia risk in diabetics taking insulin or sulfonylureas, and the unfortunate reality that most over-the-counter ALA products are racemic rather than pure R-ALA. This page covers the biochemistry, the diabetic neuropathy evidence, the chelation debate, stacking with glutathione-system and mitochondrial nutrients, and practical dosing considerations.", "activeIngredient": "Alpha-Lipoic Acid", "mechanismOfAction": "Alpha-lipoic acid has two distinct biological identities. The endogenous pool — synthesized by mitochondrial lipoic acid synthase (LIAS) and covalently attached to specific lysine residues on dehydrogenase complex subunits — is catalytically essential and not meaningfully affected by dietary or supplemental ALA. The supplemental pool — absorbed from the gut, transiting plasma and tissues, cycling between oxidized ALA and reduced dihydrolipoic acid (DHLA), and eventually metabolized and excreted — is what produces the clinical effects of ALA supplementation. Understanding this distinction resolves most of the confusion around ALA pharmacology. ENDOGENOUS ALA AS ENZYME COFACTOR. In mitochondria, lipoic acid is synthesized de novo from octanoic acid (an 8-carbon fatty acid) by LIAS, which inserts two sulfur atoms between C6 and C8 to form the characteristic dithiolane ring. The resulting lipoyl group is transferred to specific lysine residues on the E2 (dihydrolipoyl acyltransferase) subunits of the dehydrogenase complexes — pyruvate dehydrogenase, α-ketoglutarate dehydrogenase, branched-chain ketoacid dehydrogenase, 2-oxoadipate dehydrogenase, and the glycine cleavage system H-protein. In catalysis, the lipoyl arm swings between the E1 (decarboxylase), E2 (acyltransferase), and E3 (dihydrolipoyl dehydrogenase) active sites, receiving an acyl group from a thiamine-bound intermediate, transferring it to CoA, and delivering reducing equivalents to FAD on E3. This mechanism is exquisitely conserved from bacteria to humans and is the reason lipoic acid is essential for aerobic energy metabolism and amino acid catabolism. Supplemental ALA does not supply enzyme-bound lipoic acid because the biosynthetic pathway is compartmentalized and the attachment to E2 subunits occurs co-translationally or post-translationally from endogenous synthesis, not from dietary uptake. REDOX CYCLING OF FREE ALA/DHLA. Supplemental ALA enters cells, where it is reduced by NADH or NADPH-dependent enzymes (mitochondrial dihydrolipoamide dehydrogenase, cytosolic thioredoxin reductase, glutathione reductase) to dihydrolipoic acid. The ALA/DHLA couple has a redox potential of approximately -320 mV, making DHLA one of the most powerful biological reductants — more reducing than glutathione (GSSG/2GSH = -240 mV) and capable of reducing most oxidized biological thiols. Because both ALA and DHLA are amphipathic, they partition into both aqueous and lipid environments and can quench oxidants across the cellular landscape. DHLA directly scavenges hydroxyl radicals, hypochlorous acid, peroxyl radicals, peroxynitrite, and singlet oxygen. Both ALA and DHLA chelate transition metals (particularly Cu2+, Fe2+, Mn2+, Zn2+) that catalyze Fenton-type radical generation. REGENERATION OF OTHER ANTIOXIDANTS. Packer's \"universal antioxidant\" framing rests on DHLA's capacity to regenerate oxidized forms of other antioxidants: DHLA reduces dehydroascorbate (oxidized vitamin C) back to ascorbate, allowing vitamin C to re-engage in reducing chemistry; DHLA reduces glutathione disulfide (GSSG) to glutathione (GSH); DHLA reduces tocopheroxyl radical (oxidized vitamin E) back to α-tocopherol through an indirect path via ascorbate or directly; DHLA can reduce ubiquinone (oxidized CoQ10) to ubiquinol. This interconnected web allows cells to maintain reduced antioxidant pools under oxidative stress in ways that individual antioxidants alone cannot. INSULIN SENSITIVITY AND GLUCOSE DISPOSAL. ALA has well-documented insulin-sensitizing effects that are distinct from its antioxidant activity. Intravenous ALA 600 mg produces acute improvements in insulin-mediated glucose disposal in type 2 diabetic patients (Jacob et al), with effect sizes comparable to low-dose insulin-sensitizers. The mechanism involves increased GLUT4 translocation to the plasma membrane of muscle and adipose cells, activation of AMP-activated protein kinase (AMPK) in liver and muscle, modulation of tyrosine phosphorylation of the insulin receptor and IRS-1, and improved endothelial function with enhanced nitric oxide-mediated vasodilation. Oral ALA at 600-1800 mg/day produces more modest but measurable improvements in HOMA-IR, fasting glucose, and HbA1c in metabolic syndrome and type 2 diabetes, though effect sizes are smaller than metformin or GLP-1 agonists. DIABETIC NEUROPATHY MECHANISMS. The neuropathy protection observed in ALADIN and NATHAN trials reflects multiple convergent mechanisms. Hyperglycemia in diabetes drives pathological glucose metabolism through four damage pathways: increased polyol pathway flux (sorbitol/fructose accumulation in neural tissue), increased advanced glycation end-product formation, activation of protein kinase C isoforms, and increased hexosamine pathway flux. All four pathways generate mitochondrial superoxide as a common final mediator. ALA intercepts mitochondrial ROS, protects polyunsaturated fatty acids in nerve membranes from lipid peroxidation, and improves endoneurial blood flow through enhanced nitric oxide-mediated vasodilation. Clinically, this translates to reduced neuropathic pain, improved vibration sensitivity, and preserved nerve conduction velocity — effects that accumulate over months of therapy. R vs S ENANTIOMERS. The natural enantiomer is R-(+)-lipoic acid; S-(−)-lipoic acid is present only in chemically synthesized material. Commercial racemic ALA is a 50:50 mixture. Biochemically, R-ALA is the form recognized by LIAS and by the enzymes that reduce ALA to DHLA; S-ALA is poorly metabolized and may even competitively inhibit R-ALA pharmacology in some systems. Pharmacokinetic studies show that oral R-ALA has approximately 40% higher peak plasma concentrations than the racemic mixture at equivalent total doses (Hermann et al). Stabilized sodium R-lipoate formulations (Na-R-ALA) further improve bioavailability by 10-30% over free R-ALA due to better solubility and less pre-systemic degradation. For most indications, R-ALA or Na-R-ALA at lower doses (200-600 mg) achieves equivalent or superior effects to racemic ALA at higher doses (600-1200 mg), but the price differential is substantial. HEAVY METAL CHELATION. DHLA contains two thiol groups at positions 6 and 8 of the pentanoic acid backbone, oriented such that they can coordinate soft Lewis acid metal cations. Mercury (Hg2+ and methylmercury), arsenic (As3+), lead (Pb2+), and cadmium (Cd2+) form stable complexes with DHLA, and the resulting chelate is more hydrophilic than the free metal, promoting renal excretion. ALA's small size (molecular weight 206) allows it to cross cell membranes and the blood-brain barrier, distinguishing it from larger chelators like DMSA or EDTA that cannot access intracellular or CNS mercury pools. This tissue penetration is the basis for Cutler's protocol for methylmercury mobilization. However, the short plasma half-life of ALA (30-60 minutes after oral dosing) means that single doses produce transient chelation followed by redistribution — which is why Cutler protocols specify dosing every 3-4 hours around the clock during active chelation rounds, a substantial adherence burden. PHARMACOKINETICS. Oral ALA is absorbed via monocarboxylate transporters in the small intestine with bioavailability of 20-40% for racemic ALA and 40-60% for R-ALA; taking on empty stomach and separately from high-carbohydrate meals improves absorption significantly. Peak plasma concentrations occur 30-60 minutes post-dose. The half-life is 30-60 minutes; ALA undergoes extensive first-pass hepatic metabolism via β-oxidation of the pentanoic acid tail, S-methylation, and oxidation, producing a family of metabolites including bisnorlipoic acid, tetranorlipoic acid, and their β-oxidized sulfur-oxidized derivatives. The short half-life means that sustained plasma exposure requires either frequent dosing or sustained-release formulations; most commercial products are immediate-release and produce brief peak exposures followed by rapid clearance. Despite this, the biological effects of ALA (particularly on insulin sensitivity and neuropathy) accumulate over weeks of dosing, suggesting that either tissue accumulation or downstream signaling changes mediate the sustained effects rather than moment-to-moment plasma concentration. BIOTIN COMPETITION. ALA and biotin share structural similarities (both contain sulfur-heterocyclic rings fused to a pentanoic acid-like tail) and use the same intestinal uptake transporter (sodium-dependent multivitamin transporter, SMVT). High-dose ALA competitively inhibits biotin absorption and can induce functional biotin deficiency with chronic use at doses ≥600 mg/day (Zempleni et al). Since biotin is required for four carboxylase enzymes (acetyl-CoA carboxylase, pyruvate carboxylase, propionyl-CoA carboxylase, β-methylcrotonyl-CoA carboxylase), biotin deficiency can produce its own metabolic consequences. Co-supplementation with biotin 2-5 mg/day is standard for chronic high-dose ALA protocols.", "legalStatus": "Not approved for human use — research chemical", "warning": "For research purposes only. Not for human consumption." } }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Does alpha-lipoic acid actually help with diabetic neuropathy, or is this just marketing?", "acceptedAnswer": { "@type": "Answer", "text": "The diabetic neuropathy evidence for ALA is among the strongest evidence bases for any supplement. Multiple randomized controlled trials — ALADIN (PMID 7589950), ALADIN III (PMID 10391387), SYDNEY 2 (PMID 17140036), and the four-year NATHAN 1 (PMID 21953615) — consistently demonstrate that 600 mg/day of oral ALA meaningfully reduces neuropathic symptoms (pain, burning, paresthesias, numbness) and improves nerve conduction in type 1 and type 2 diabetics. The effect sizes are clinically meaningful and comparable to pharmaceutical options like duloxetine or pregabalin. Germany has licensed ALA at 600 mg/day as a prescription medication for diabetic polyneuropathy since the 1960s based on this evidence. Expected timeline: symptom improvement over 3-5 weeks of oral therapy, with greater improvements if started with IV loading at a functional medicine clinic. This is one of the few supplements where the evidence base rivals or exceeds pharmaceutical alternatives, and where clinical practice in one major country has formally recognized the benefit." } }, { "@type": "Question", "name": "Is R-ALA really better than racemic, or is that just expensive marketing?", "acceptedAnswer": { "@type": "Answer", "text": "R-ALA is biologically superior — it''s the natural enantiomer used by human enzymes, while the synthetic S-ALA in racemic mixtures is poorly metabolized and may even competitively inhibit R-ALA pharmacology. Pharmacokinetic studies (Hermann PMID 17024766) show R-ALA has approximately 40% higher peak plasma concentrations and 2-3x higher AUC than racemic at equivalent total doses. In practice, 300 mg R-ALA approximates 600 mg racemic. Whether this is worth the roughly 2-3x price premium depends on context. For general antioxidant support, racemic at higher doses is fine and cost-effective. For clinical indications (diabetic neuropathy, insulin resistance) where the trial evidence used racemic, matching the trial dose (600 mg racemic) is reasonable. For users with GI intolerance to high-dose racemic, R-ALA at lower doses achieves the same effects with less GI burden. Stabilized sodium R-lipoate (Na-R-ALA) further improves bioavailability and is worth the premium for serious users. Beware that some products marketed as \"R-ALA\" are racemic — purchase from reputable suppliers with third-party verification." } }, { "@type": "Question", "name": "Can ALA really help me lose weight?", "acceptedAnswer": { "@type": "Answer", "text": "The weight-loss effect of ALA is real but modest. Meta-analyses (Namazi PMID 28456476; Kucukgoncu PMID 27702795) found that ALA at 600-1800 mg/day produces approximately 1-2 kg additional weight loss over placebo during 8-20 week trials. The mechanism involves AMPK activation in the hypothalamus (reduced appetite) and peripheral tissues (enhanced fatty acid oxidation), plus improved insulin sensitivity. This is a meaningful but small effect — ALA is not a primary weight-loss intervention, comparable perhaps to modest dietary changes rather than medications like GLP-1 agonists. ALA may be a reasonable adjunct for users pursuing comprehensive lifestyle-based weight management, particularly those with insulin resistance or metabolic syndrome where ALA''s other benefits compound. Do not expect dramatic results from ALA monotherapy for obesity." } }, { "@type": "Question", "name": "Do I need to worry about hypoglycemia from ALA?", "acceptedAnswer": { "@type": "Answer", "text": "Yes, if you''re diabetic on insulin, sulfonylureas, or meglitinides. ALA''s insulin-sensitizing effects can precipitate symptomatic hypoglycemia, particularly during the first 2-4 weeks of initiation or dose increase. Check blood glucose more frequently during this window, and anticipate that insulin or sulfonylurea doses may need reduction (often 10-20%). Discuss ALA with your prescribing clinician before starting if on these medications. For diabetics on metformin alone, hypoglycemia risk is low because metformin itself rarely causes hypoglycemia. For non-diabetics, clinically significant hypoglycemia from ALA is uncommon but has been reported, especially with high doses on empty stomach combined with low-carbohydrate eating or fasting. If you experience symptoms of hypoglycemia (shakiness, sweating, confusion, palpitations) after ALA, check blood glucose if possible and eat some carbohydrate. Persistent issues warrant reducing ALA dose or discontinuation." } }, { "@type": "Question", "name": "Should I take ALA with food or on empty stomach?", "acceptedAnswer": { "@type": "Answer", "text": "Empty stomach — 30-60 minutes before a meal or 2 hours after — produces approximately 30-50% higher plasma concentrations than taking with food, particularly carbohydrate-rich meals. Take your ALA in the morning fasted, or pre-workout, or well before lunch. If empty stomach causes GI upset (nausea, heartburn), a small amount of protein (e.g., a handful of nuts, a small piece of cheese) represents a reasonable compromise that preserves most of the absorption advantage. Avoid taking with large mixed meals. Some commercial products use time-release technology or liposomal delivery to reduce GI irritation, but this may also reduce peak plasma exposure and thus reduce insulin-sensitivity effects — simple immediate-release with empty-stomach dosing is the best balance for most users. If you''re on levothyroxine for thyroid, take it morning fasted and separate your ALA by at least 4 hours (typically ALA with lunch or late afternoon)." } }, { "@type": "Question", "name": "Is ALA safe long-term?", "acceptedAnswer": { "@type": "Answer", "text": "Yes, generally. The longest controlled safety data comes from NATHAN 1, a 4-year trial of 600 mg/day in diabetic polyneuropathy patients with no major safety signals (PMID 21953615). German clinical practice has used 300-600 mg/day for neuropathy for decades without emerging safety concerns. Chronic use at standard doses (300-600 mg/day) appears very safe. The main considerations for long-term users are: (1) biotin replacement — chronic high-dose ALA competes with biotin absorption at the SMVT transporter, producing functional biotin deficiency over months; add biotin 2-5 mg/day to prevent this; (2) occasional monitoring of liver enzymes, glucose, and thyroid function if on chronic high-dose; (3) awareness of insulin autoimmune syndrome risk in Asian populations; (4) appropriate adjustments for concurrent diabetes medications. At standard doses with these precautions, ALA is among the safer supplements for indefinite use. Very high doses (≥1800 mg/day) for extended periods have less long-term data and should be reserved for specific indications with medical oversight." } }, { "@type": "Question", "name": "Does ALA actually chelate mercury and other heavy metals?", "acceptedAnswer": { "@type": "Answer", "text": "Biochemically, yes — dihydrolipoic acid (DHLA, the reduced form of ALA) has two thiol groups in an orientation that forms stable complexes with mercury, arsenic, lead, and cadmium, and ALA''s small size allows intracellular and CNS penetration that larger chelators like DMSA can''t achieve. Whether it works clinically depends heavily on the protocol. The Andrew Cutler protocols specify dosing every 3-4 hours around the clock during active \"rounds\" because ALA''s short half-life (30-60 minutes) means that single or twice-daily dosing can mobilize mercury from tissues faster than the body excretes it, potentially causing redistribution to sensitive tissues including the brain. For documented heavy metal toxicity, mainstream occupational and toxicology medicine still prefers DMSA or DMPS as first-line chelators — they have more controlled clinical trial evidence and simpler dosing. ALA has a legitimate role in integrative chelation protocols but should be pursued with a clinician experienced in heavy metal therapy, not as a DIY project. For users concerned about mercury from dental amalgams or fish consumption without documented toxicity, ALA''s general antioxidant support is reasonable and low-risk, while aggressive chelation protocols require careful consideration and supervision." } }, { "@type": "Question", "name": "Will ALA interfere with my chemotherapy?", "acceptedAnswer": { "@type": "Answer", "text": "This is a genuinely unresolved question. The theoretical concern is that antioxidants may reduce the efficacy of chemotherapy agents (cisplatin, carboplatin, doxorubicin, taxanes) and radiation therapy that work through oxidative damage to cancer cells. Clinical evidence is mixed — some studies suggest ALA selectively protects healthy tissue (reducing chemotherapy-induced peripheral neuropathy) without impairing tumor response, while others raise concerns about reduced treatment efficacy. The safe default for patients on active chemotherapy or radiation is to avoid ALA and other high-dose antioxidants during treatment cycles, or to discuss with the treating oncologist before starting. Post-treatment use for established chemotherapy-induced peripheral neuropathy is much better supported and lower-risk. If your oncologist is unfamiliar with ALA specifically, asking them to review the mixed literature on antioxidants during chemotherapy is reasonable — the answer often depends on the specific drug, cancer type, and treatment goals." } }, { "@type": "Question", "name": "Can ALA help with insulin resistance or metabolic syndrome even if I''m not diabetic?", "acceptedAnswer": { "@type": "Answer", "text": "Yes, to a modest degree. Meta-analyses show that ALA 600-1800 mg/day produces measurable but modest improvements in HOMA-IR (insulin resistance index), fasting glucose, HbA1c, and triglycerides in metabolic syndrome and pre-diabetes (Akbari PMID 29361170). Effect sizes are smaller than metformin or GLP-1 agonists but real. For non-diabetics pursuing metabolic optimization, ALA is a reasonable component of a comprehensive approach that also emphasizes exercise, diet, weight management, magnesium, and other insulin-supportive nutrients. Expect modest improvements in HOMA-IR over 3-6 months. If pre-diabetic with significant insulin resistance, consider combining ALA with berberine 500 mg 2-3x daily and metformin if prescribed by your clinician for additive AMPK activation. Don''t expect ALA alone to resolve serious metabolic dysfunction without concurrent lifestyle intervention." } }, { "@type": "Question", "name": "Why do I need to take biotin with ALA?", "acceptedAnswer": { "@type": "Answer", "text": "Because ALA and biotin share the same intestinal uptake transporter (sodium-dependent multivitamin transporter, SMVT) and have similar structural features. At doses ≥600 mg/day for more than a few months, ALA competitively inhibits biotin absorption and can induce functional biotin deficiency (Zempleni PMID 19348577). Biotin is required for four critical carboxylase enzymes in fatty acid, branched-chain amino acid, and odd-chain fatty acid metabolism, and deficiency symptoms include hair thinning, brittle nails, dermatitis, muscle pain, and in severe cases neurological effects. The solution is simple and cheap: add biotin 2-5 mg/day when taking chronic ALA ≥600 mg/day. Many commercial ALA products include biotin for this reason — check the label. Note that high-dose biotin can interfere with several laboratory immunoassays (thyroid function, cardiac troponin, hormone tests), so pause biotin for 48-72 hours before testing if your labs will be affected. For chronic ALA users not taking biotin, look for subtle signs of deficiency (hair and nail changes, skin issues) and add biotin empirically if they appear." } } ] }, { "@context": "https://schema.org", "@type": "Organization", "@id": "https://www.bodyhackguide.co#organization", "name": "BodyHackGuide", "alternateName": "BHG", "url": "https://www.bodyhackguide.co", "logo": { "@type": "ImageObject", "url": "https://www.bodyhackguide.co/logo.png", "width": 512, "height": 512 }, "description": "Evidence-based research reference for peptides and nootropics. 124+ compound profiles, interactive dosing calculators, real-time vendor pricing, and trust-scored vendor reviews scored on a public, reproducible methodology applied to every vendor. BodyHackGuide and BHG Labs share common ownership, and we earn a commission on purchases through our links.", "foundingDate": "2024", "founder": { "@id": "https://www.bodyhackguide.co/about#person" }, "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher", "https://discord.gg/Mhq5UdRYBA" ], "knowsAbout": [ "Peptide research", "Nootropic research", "Biohacking", "Compound dosing", "Vendor transparency" ], "publishingPrinciples": "https://www.bodyhackguide.co/editorial-standards", "ethicsPolicy": "https://www.bodyhackguide.co/editorial-standards", "diversityPolicy": "https://www.bodyhackguide.co/editorial-standards" } ] --- [Skip to content](#main-content) ## Research Use Only This site is an **educational resource** for research compounds. We do **not endorse** human consumption of any compound. BodyHackGuide and **BHG Labs share common ownership**; we rank every vendor on the same public methodology, and we earn a commission on purchases through our links. By entering, you confirm you are **21 years of age or older** and agree to our [Terms](/terms) & [Privacy Policy](/privacy). I'm 21+ — Enter SiteLeave site [![BodyHackGuide](/assets/bodyhackguide-logo-DOzZNUyh.webp)BodyHackGuide ](/) [Compare](/compare)[Wiki](/wiki)[Vendors](/vendors)[Deals](/deals)[Stacks](/stack-builder)[Nootropics](/nootropics)[Tools](/tools) Learn Community Search ⌘K [Sign In](/auth?returnTo=%2Fcompound%2Falpha-lipoic-acid) 100K+ researchers trust BodyHackGuide — Join [r/BodyHackGuide](https://reddit.com/r/bodyhackguide) 1. [Home](/) 2. [Compounds](/compare) 3. Alpha-Lipoic Acid [Where to buy Alpha-Lipoic Acid](/buy/alpha-lipoic-acid) [Alpha-Lipoic Acid coupon codes](/coupons/alpha-lipoic-acid) [Alpha-Lipoic Acid protocol](/protocol/alpha-lipoic-acid) [Alternatives to Alpha-Lipoic Acid](/alternatives-to/alpha-lipoic-acid) [Alpha-Lipoic Acid side effects](/side-effects/alpha-lipoic-acid) 1. [Home](/) 3. [Compounds](/compare) 5. Alpha-Lipoic Acid # Alpha-Lipoic Acid Foundational Preclinical Download PDF Also known as: ALA, α-Lipoic acid, Alpha lipoic acid, Thioctic acid, R-Lipoic acid, R-ALA, R-(+)-Lipoic acid, S-Lipoic acid, Na-R-ALA, Sodium R-lipoate, Lipoate, 1,2-Dithiolane-3-pentanoic acid Alpha-lipoic acid (ALA), also known as thioctic acid or 1,2-dithiolane-3-pentanoic acid, is a sulfur-containing eight-carbon fatty acid derivative synthesized endogenously in mitochondria by lipoic acid synthase (LIAS). In its native biological role, ALA serves as an essential cofactor for five critical mitochondrial dehydrogenase enzyme complexes: pyruvate dehydrogenase (the gateway from glycolysis to the citric acid cycle), α-ketoglutarate dehydrogenase (a rate-limiting TCA cycle enzyme), branched-chain α-ketoacid dehydrogenase (metabolizing leucine, isoleucine, and valine), 2-oxoadipate dehydrogenase, and the glycine cleavage system. Last reviewed: May 4, 2026 [ Foundational Category ](/wiki#cat-foundational) Preclinical Research Stage OverviewChemical InfoDosing & ProtocolsInteractionsResearchCompare PricesRelated ## Overview ### At A Glance Mechanism Alpha-lipoic acid has two distinct biological identities. The endogenous pool — synthesized by mitochondrial lipoic acid synthase (LIAS) and covalently attached to specific lysine residues on dehydrogenase complex subunits — is catalytically essential and not meaningfully affecte… ### Overview Alpha-lipoic acid (ALA), also known as thioctic acid or 1,2-dithiolane-3-pentanoic acid, is a sulfur-containing eight-carbon fatty acid derivative synthesized endogenously in mitochondria by lipoic acid synthase (LIAS). In its native biological role, ALA serves as an essential cofactor for five critical mitochondrial dehydrogenase enzyme complexes: pyruvate dehydrogenase (the gateway from glycolysis to the citric acid cycle), α-ketoglutarate dehydrogenase (a rate-limiting TCA cycle enzyme), branched-chain α-ketoacid dehydrogenase (metabolizing leucine, isoleucine, and valine), 2-oxoadipate dehydrogenase, and the glycine cleavage system. In all these roles, ALA is covalently attached via an amide bond to a specific lysine residue on a dihydrolipoyl-binding subunit, where it serves as a "swinging arm" that shuttles acyl groups and reducing equivalents between catalytic sites. Loss of lipoic acid synthase function produces a catastrophic inherited metabolic disease; no human can live without endogenous ALA. When taken as a dietary supplement, exogenous ALA does not meaningfully replace or supplement the endogenous enzyme-bound lipoic acid — the biosynthetic pathway is tightly compartmentalized, and supplemental ALA does not become covalently attached to dehydrogenase complexes. Instead, supplemental ALA exerts its biological effects through a different mechanism: it exists transiently in the plasma and cytoplasm as a free molecule and redox couple with dihydrolipoic acid (DHLA), where it functions as one of the most versatile antioxidants known in human biology. Unlike most antioxidants that are restricted to either water-soluble or lipid-soluble compartments, ALA and DHLA are amphipathic — they function effectively in both aqueous cytoplasm and lipid membranes, enabling them to quench free radicals across the cellular landscape. Lester Packer's seminal reviewdesignated ALA a "universal antioxidant" in recognition of this dual-phase activity and its capacity to regenerate oxidized forms of vitamin C, vitamin E, glutathione, and CoQ10 back to their active reduced states. This regenerative function makes ALA a keystone in the network of cellular antioxidant recycling. The strongest clinical evidence for supplemental ALA is in diabetic neuropathy, where Germany has licensed ALA at 600 mg/day since the 1960s based on the ALADIN series of randomized trials (PMIDs 7589950, 10391387), the SYDNEY 2 trial, and the four-year NATHAN 1 study. These trials established that 600 mg/day of oral ALA meaningfully reduces neuropathic symptoms (pain, burning, paresthesias, numbness) and improves nerve conduction in patients with type 1 and type 2 diabetes. The mechanism appears to combine direct antioxidant protection of vulnerable peripheral nerves, improved microvascular perfusion via nitric oxide enhancement, modulation of polyol and hexosamine pathway damage from hyperglycemia, and genuine insulin-sensitizing effects on glucose disposal. Beyond neuropathy, ALA has been investigated for insulin resistance and metabolic syndrome, non-alcoholic fatty liver disease, mitochondrial disorders, stroke recovery, burning mouth syndrome, and weight management — with evidence quality and effect sizes varying widely. ALA also has a small but important role in heavy metal chelation, particularly mercury and arsenic. The dithiol structure of dihydrolipoic acid (DHLA, the reduced form of ALA) can bind soft metal cations. Andrew Cutler's protocols for mercury detoxification popularized ALA as a chelator among biohackers; while the mainstream chelation medical community uses DMSA or DMPS as first-line agents, ALA has an established but more peripheral role. The protocol logic depends on careful dosing schedules that respect the short plasma half-life (30-60 minutes) of ALA to avoid mobilizing mercury from stable deposits faster than the body can excrete it. For BodyHackGuide readers, ALA represents an antioxidant with legitimate clinical evidence in specific indications, meaningful insulin-sensitizing effects, and a niche role in mitochondrial support — but it is not a "clean" supplement in the sense that vitamin D or magnesium are. ALA requires attention to isomer selection (R-ALA is the natural form with better bioavailability; S-ALA is the synthetic enantiomer present in racemic commercial products), absorption tuning (empty stomach is important), biotin competition (chronic high-dose ALA can induce functional biotin deficiency), hypoglycemia risk in diabetics taking insulin or sulfonylureas, and the unfortunate reality that most over-the-counter ALA products are racemic rather than pure R-ALA. This page covers the biochemistry, the diabetic neuropathy evidence, the chelation debate, stacking with glutathione-system and mitochondrial nutrients, and practical dosing considerations. ## Chemical Information IUPAC Name Not yet available CAS Number Not yet available Molecular Formula Not yet available Molecular Mass Not yet available Chemical data is being compiled for this compound. ## Dosing & Protocols ### Unlock Dosing Protocols Free account gets you: - View beginner, intermediate & advanced protocols - See weight-based dosing calculations - Access cycle length & frequency data [Create free account](/auth)[Sign in](/auth) 2,800+ researchers already in ## Research ### Unlock Research Data Free account gets you: - Browse PubMed study summaries - See clinical trial phases & results - Access mechanism of action details [Create free account](/auth)[Sign in](/auth) 2,800+ researchers already in ## Interactions ### Contraindications Alpha-lipoic acid is well-tolerated for most users at standard doses, but several clinical scenarios warrant caution, dose modification, or avoidance. DIABETES WITH INSULIN OR SULFONYLUREA THERAPY (USE WITH MONITORING). The most important clinical interaction: ALA has insulin-sensitizing effects that can precipitate hypoglycemia in patients on insulin, sulfonylureas (glipizide, glyburide, glimepiride), or meglitinides (repaglinide, nateglinide). This is NOT a contraindication but requires more frequent blood glucose monitoring during the first 2-4 weeks of ALA initiation, and insulin or sulfonylurea doses may need to be reduced (often by 10-20%) to prevent symptomatic hypoglycemia. Discuss with prescribing clinician before starting ALA if on these medications. INSULIN AUTOIMMUNE SYNDROME (HIRATA DISEASE) RISK. Asian populations, particularly Japanese and Korean with HLA-DRB1\*04:06 haplotype, have documented risk of developing insulin autoimmune syndrome triggered by ALA. This rare condition produces spontaneous hypoglycemia due to anti-insulin antibodies and typically resolves weeks to months after ALA discontinuation. Users of Asian ancestry should be aware; consider avoiding chronic high-dose ALA if family history of autoimmune conditions. This risk is substantially lower in Caucasian and other populations due to HLA distribution differences. PREGNANCY. Avoid ALA supplementation during pregnancy unless specifically indicated by a clinician managing a high-risk condition; safety data in pregnancy is insufficient, and ALA is not a standard pregnancy supplement. The theoretical antioxidant benefit is outweighed by uncertainty. LACTATION. Limited data on ALA in breast milk; standard recommendation is to avoid during breastfeeding or to consult with clinician if specifically indicated. PEDIATRIC USE. ALA has limited safety data in children. Use should be reserved for specific medical indications (e.g., primary mitochondrial disease) under pediatric metabolic genetics supervision. Routine supplementation in healthy children is not appropriate. THIAMINE (B1) DEFICIENCY. Severe thiamine deficiency (classical beriberi, Wernicke-Korsakoff syndrome, severe alcoholism) should be corrected with parenteral thiamine before initiating ALA. ALA activates thiamine-dependent enzymes (pyruvate dehydrogenase, α-ketoglutarate dehydrogenase), and in thiamine-depleted tissues this can exacerbate the clinical manifestations of thiamine deficiency before repletion. ACTIVE CHEMOTHERAPY OR RADIATION THERAPY. Theoretical concern: antioxidants may reduce efficacy of chemotherapy agents that work through oxidative damage (cisplatin, carboplatin, doxorubicin, taxanes) or ionizing radiation. Clinical evidence is mixed — some studies show ALA selectively protects healthy tissue without impairing tumor response, others suggest potential interference with treatment efficacy. Patients on active cancer treatment should discuss ALA with their oncology team rather than self-supplementing. Post-treatment use for prevention of chemotherapy-induced peripheral neuropathy is better supported. SEVERE HEPATIC IMPAIRMENT. While ALA is hepatoprotective in most studies (benefits in NAFLD, acetaminophen toxicity), severe decompensated cirrhosis warrants caution with any supplement. Monitor liver enzymes and avoid high doses in advanced hepatic dysfunction. ACUTE PORPHYRIA. Theoretical concern based on sulfur metabolism interactions; data are lacking but standard caution applies to users with porphyria. ALLERGIC REACTION. Rare but documented allergy to ALA warrants discontinuation and avoidance of all forms (oral and IV). Cross-reactivity with other disulfide-containing compounds is not established. SEVERE HYPOGLYCEMIA HISTORY. Patients with frequent severe hypoglycemic episodes (with or without awareness) should initiate ALA with close monitoring, particularly if on insulin or sulfonylureas. SEVERE GASTROINTESTINAL DISEASE. Active peptic ulcer disease, severe gastritis, or refractory GERD may be exacerbated by ALA's irritant effects on upper GI mucosa. Consider reduced doses (100-300 mg) or enteric-coated formulations, or avoid until GI symptoms are controlled. THIOL SENSITIVITY. Rare patients with sulfa allergy or sulfur-containing drug sensitivities may be more likely to experience adverse reactions; monitor closely or avoid if indicated. HEAVY ALCOHOL USE. Chronic heavy alcohol use damages thiamine status, B12 status, liver function, and neurological integrity; ALA may be beneficial in this context but should be part of a complete nutritional repletion program including thiamine, B12, folate, and other deficient nutrients. Avoid as monotherapy in heavy drinkers without broader nutritional support. SURGERY. Discontinue ALA 1-2 weeks before elective surgery due to potential hypoglycemic effects and theoretical interactions with anesthesia; resume post-operatively once stable. Patients on chronic ALA for diabetic neuropathy may continue through the perioperative period with glucose monitoring at the surgical team's discretion. DRUG INTERACTIONS OF NOTE. Besides insulin/sulfonylureas already mentioned: levothyroxine (separate by ≥4 hours due to reduced absorption), cisplatin and other oxidative chemotherapy (discuss with oncologist), warfarin (no significant interaction established but prudent to monitor INR when starting), thyroid hormone more generally (modest effects on T3/T4 conversion), and other insulin sensitizers like pioglitazone (additive glucose-lowering effect, monitor). DOSE ADJUSTMENT FOR KIDNEY DISEASE. Standard dosing is generally safe in mild-to-moderate chronic kidney disease. For advanced CKD (eGFR <30) or dialysis, consider starting at lower dose (100-300 mg) and monitoring for accumulation of metabolites and any unusual effects. ALA is partly eliminated by urinary excretion of sulfur-containing metabolites. Research Disclaimer This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds. [Sign in for alerts ](/auth) No listings found for Alpha-Lipoic Acid. Get Alpha-Lipoic Acid Price Drop Alerts Set a target price and we'll notify you when any vendor drops below it. [Sign in to set alerts](/auth) ### Sign in to leave a review Reviews on BodyHackGuide are tied to verified user accounts and moderated before publishing. Sign in (free, no spam) to share your experience with Alpha-Lipoic Acid. [Sign in](/auth) ### Related Compounds [View All](/wiki) [ ### Coenzyme Q10 Foundational Preclinical Coenzyme Q10 (CoQ10), also known as ubiquinone-10, ubidecarenone, or simply "coenzyme Q," is a lipid-soluble benzoquinone compound with a 50-carbon isoprenoid side chain (decaprenyl tail) that anchors it within the inner mitochondrial membrane. Preclinical View Profile ](/compound/coq10)[ ### Creatine Foundational Preclinical Creatine is the most-researched nutritional supplement in sports science and has emerged over the past decade as a cornerstone compound in the broader longevity conversation, extending beyond its traditional ergogenic applications into cognitive performance, brain health in aging, sarcopenia prevention, bone health, and recovery from traumatic brain injury. Preclinical View Profile ](/compound/creatine)[ ### Glycine Foundational Preclinical Glycine is the simplest amino acid—a single hydrogen atom replacing the typical side chain found in other proteinogenic amino acids—yet it performs an wide range of biological functions. Preclinical View Profile ](/compound/glycine)[ ### Magnesium Foundational Preclinical Magnesium is the fourth most abundant cation in the human body and the second most abundant intracellular cation after potassium, with approximately 25 grams present in a typical adult—roughly 60% stored in bone, 27% in muscle, 6-7% in other soft tissues, and less than 1% in extracellular fluid including serum. 1 studies View Profile ](/compound/magnesium)[ ### Omega-3 Fatty Acids Foundational Preclinical Omega-3 fatty acids represent one of the most thoroughly researched nutritional interventions of the past half-century, with thousands of clinical trials, dozens of major meta-analyses, regulatory approvals for specific pharmaceutical preparations, and foundational status in cardiovascular medicine, cognitive health, and inflammatory conditions. 12 studies View Profile ](/compound/omega-3-fatty-acids)[ ### Selenium Foundational Preclinical Selenium is an essential trace mineral first recognized as toxic in livestock grazing on seleniferous soils in the American West (reported by Kit Carson's expedition in the 1850s) and only later, in 1957, identified as essential for mammalian life when Klaus Schwarz discovered it prevented liver necrosis in rats deficient in the newly-described "Factor 3." The subsequent decades revealed that selenium's essentiality derives from its incorporation into approximately 25 distinct selenoproteins in humans, where it appears as the 21st genetically-encoded amino acid selenocysteine (Sec, U) at specific active sites. 20 studies View Profile ](/compound/selenium) ### Side-by-Side Comparisons [All Comparisons](/compare) [Alpha-Lipoic Acid vs Glutathione](/compare/alpha-lipoic-acid-vs-glutathione "Alpha Lipoic Acid vs Glutathione") [ View Full Dosage Guide → Protocols, calculator & safety for Alpha-Lipoic Acid ](/guides/dosage/alpha-lipoic-acid) ### Related Articles [All Posts](/blog) [ #### Glutathione (GSH): What the Research Actually Supports A grounded research reference on glutathione (GSH), the body's master endogenous antioxidant. Covers the redox biology, the strongest clinical anchor (the NAC/acetaminophen-overdose antidote), the mixed skin-whitening and Parkinson's literature, the central oral bioavailability problem, and how the research community actually discusses precursors like NAC. Research-use-only, not medical advice. 7/1/2026 ](/blog/glutathione-research-guide) ### Research Score 15 0 PubMed studies ### Quality Indicators Data Completeness 50% Description Mechanism of Action Chemical Data Dosing Protocols Safety Profile PubMed Studies Interactions Vendor Listings ### Quick Facts Trial Phase Preclinical [Full Dosage Guide](/guides/dosage/alpha-lipoic-acid)[Calculate Your Dose](/tools/reconstitution) Research Disclaimer This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use. ## Frequently Asked Questions Does alpha-lipoic acid actually help with diabetic neuropathy, or is this just marketing? The diabetic neuropathy evidence for ALA is among the strongest evidence bases for any supplement. Multiple randomized controlled trials — ALADIN (PMID 7589950), ALADIN III (PMID 10391387), SYDNEY 2 (PMID 17140036), and the four-year NATHAN 1 (PMID 21953615) — consistently demonstrate that 600 mg/day of oral ALA meaningfully reduces neuropathic symptoms (pain, burning, paresthesias, numbness) and improves nerve conduction in type 1 and type 2 diabetics. The effect sizes are clinically meaningful and comparable to pharmaceutical options like duloxetine or pregabalin. Germany has licensed ALA at 600 mg/day as a prescription medication for diabetic polyneuropathy since the 1960s based on this evidence. Expected timeline: symptom improvement over 3-5 weeks of oral therapy, with greater improvements if started with IV loading at a functional medicine clinic. This is one of the few supplements where the evidence base rivals or exceeds pharmaceutical alternatives, and where clinical practice in one major country has formally recognized the benefit. Is R-ALA really better than racemic, or is that just expensive marketing? R-ALA is biologically superior — it''s the natural enantiomer used by human enzymes, while the synthetic S-ALA in racemic mixtures is poorly metabolized and may even competitively inhibit R-ALA pharmacology. Pharmacokinetic studies (Hermann PMID 17024766) show R-ALA has approximately 40% higher peak plasma concentrations and 2-3x higher AUC than racemic at equivalent total doses. In practice, 300 mg R-ALA approximates 600 mg racemic. Whether this is worth the roughly 2-3x price premium depends on context. For general antioxidant support, racemic at higher doses is fine and cost-effective. For clinical indications (diabetic neuropathy, insulin resistance) where the trial evidence used racemic, matching the trial dose (600 mg racemic) is reasonable. For users with GI intolerance to high-dose racemic, R-ALA at lower doses achieves the same effects with less GI burden. Stabilized sodium R-lipoate (Na-R-ALA) further improves bioavailability and is worth the premium for serious users. Beware that some products marketed as "R-ALA" are racemic — purchase from reputable suppliers with third-party verification. Can ALA really help me lose weight? The weight-loss effect of ALA is real but modest. Meta-analyses (Namazi PMID 28456476; Kucukgoncu PMID 27702795) found that ALA at 600-1800 mg/day produces approximately 1-2 kg additional weight loss over placebo during 8-20 week trials. The mechanism involves AMPK activation in the hypothalamus (reduced appetite) and peripheral tissues (enhanced fatty acid oxidation), plus improved insulin sensitivity. This is a meaningful but small effect — ALA is not a primary weight-loss intervention, comparable perhaps to modest dietary changes rather than medications like GLP-1 agonists. ALA may be a reasonable adjunct for users pursuing comprehensive lifestyle-based weight management, particularly those with insulin resistance or metabolic syndrome where ALA''s other benefits compound. Do not expect dramatic results from ALA monotherapy for obesity. Do I need to worry about hypoglycemia from ALA? Yes, if you''re diabetic on insulin, sulfonylureas, or meglitinides. ALA''s insulin-sensitizing effects can precipitate symptomatic hypoglycemia, particularly during the first 2-4 weeks of initiation or dose increase. Check blood glucose more frequently during this window, and anticipate that insulin or sulfonylurea doses may need reduction (often 10-20%). Discuss ALA with your prescribing clinician before starting if on these medications. For diabetics on metformin alone, hypoglycemia risk is low because metformin itself rarely causes hypoglycemia. For non-diabetics, clinically significant hypoglycemia from ALA is uncommon but has been reported, especially with high doses on empty stomach combined with low-carbohydrate eating or fasting. If you experience symptoms of hypoglycemia (shakiness, sweating, confusion, palpitations) after ALA, check blood glucose if possible and eat some carbohydrate. Persistent issues warrant reducing ALA dose or discontinuation. Should I take ALA with food or on empty stomach? Empty stomach — 30-60 minutes before a meal or 2 hours after — produces approximately 30-50% higher plasma concentrations than taking with food, particularly carbohydrate-rich meals. Take your ALA in the morning fasted, or pre-workout, or well before lunch. If empty stomach causes GI upset (nausea, heartburn), a small amount of protein (e.g., a handful of nuts, a small piece of cheese) represents a reasonable compromise that preserves most of the absorption advantage. Avoid taking with large mixed meals. Some commercial products use time-release technology or liposomal delivery to reduce GI irritation, but this may also reduce peak plasma exposure and thus reduce insulin-sensitivity effects — simple immediate-release with empty-stomach dosing is the best balance for most users. If you''re on levothyroxine for thyroid, take it morning fasted and separate your ALA by at least 4 hours (typically ALA with lunch or late afternoon). Is ALA safe long-term? Yes, generally. The longest controlled safety data comes from NATHAN 1, a 4-year trial of 600 mg/day in diabetic polyneuropathy patients with no major safety signals (PMID 21953615). German clinical practice has used 300-600 mg/day for neuropathy for decades without emerging safety concerns. Chronic use at standard doses (300-600 mg/day) appears very safe. The main considerations for long-term users are: (1) biotin replacement — chronic high-dose ALA competes with biotin absorption at the SMVT transporter, producing functional biotin deficiency over months; add biotin 2-5 mg/day to prevent this; (2) occasional monitoring of liver enzymes, glucose, and thyroid function if on chronic high-dose; (3) awareness of insulin autoimmune syndrome risk in Asian populations; (4) appropriate adjustments for concurrent diabetes medications. At standard doses with these precautions, ALA is among the safer supplements for indefinite use. Very high doses (≥1800 mg/day) for extended periods have less long-term data and should be reserved for specific indications with medical oversight. Does ALA actually chelate mercury and other heavy metals? Biochemically, yes — dihydrolipoic acid (DHLA, the reduced form of ALA) has two thiol groups in an orientation that forms stable complexes with mercury, arsenic, lead, and cadmium, and ALA''s small size allows intracellular and CNS penetration that larger chelators like DMSA can''t achieve. Whether it works clinically depends heavily on the protocol. The Andrew Cutler protocols specify dosing every 3-4 hours around the clock during active "rounds" because ALA''s short half-life (30-60 minutes) means that single or twice-daily dosing can mobilize mercury from tissues faster than the body excretes it, potentially causing redistribution to sensitive tissues including the brain. For documented heavy metal toxicity, mainstream occupational and toxicology medicine still prefers DMSA or DMPS as first-line chelators — they have more controlled clinical trial evidence and simpler dosing. ALA has a legitimate role in integrative chelation protocols but should be pursued with a clinician experienced in heavy metal therapy, not as a DIY project. For users concerned about mercury from dental amalgams or fish consumption without documented toxicity, ALA''s general antioxidant support is reasonable and low-risk, while aggressive chelation protocols require careful consideration and supervision. Will ALA interfere with my chemotherapy? This is a genuinely unresolved question. The theoretical concern is that antioxidants may reduce the efficacy of chemotherapy agents (cisplatin, carboplatin, doxorubicin, taxanes) and radiation therapy that work through oxidative damage to cancer cells. Clinical evidence is mixed — some studies suggest ALA selectively protects healthy tissue (reducing chemotherapy-induced peripheral neuropathy) without impairing tumor response, while others raise concerns about reduced treatment efficacy. The safe default for patients on active chemotherapy or radiation is to avoid ALA and other high-dose antioxidants during treatment cycles, or to discuss with the treating oncologist before starting. Post-treatment use for established chemotherapy-induced peripheral neuropathy is much better supported and lower-risk. If your oncologist is unfamiliar with ALA specifically, asking them to review the mixed literature on antioxidants during chemotherapy is reasonable — the answer often depends on the specific drug, cancer type, and treatment goals. Can ALA help with insulin resistance or metabolic syndrome even if I''m not diabetic? Yes, to a modest degree. Meta-analyses show that ALA 600-1800 mg/day produces measurable but modest improvements in HOMA-IR (insulin resistance index), fasting glucose, HbA1c, and triglycerides in metabolic syndrome and pre-diabetes (Akbari PMID 29361170). Effect sizes are smaller than metformin or GLP-1 agonists but real. For non-diabetics pursuing metabolic optimization, ALA is a reasonable component of a comprehensive approach that also emphasizes exercise, diet, weight management, magnesium, and other insulin-supportive nutrients. Expect modest improvements in HOMA-IR over 3-6 months. If pre-diabetic with significant insulin resistance, consider combining ALA with berberine 500 mg 2-3x daily and metformin if prescribed by your clinician for additive AMPK activation. Don''t expect ALA alone to resolve serious metabolic dysfunction without concurrent lifestyle intervention. Why do I need to take biotin with ALA? Because ALA and biotin share the same intestinal uptake transporter (sodium-dependent multivitamin transporter, SMVT) and have similar structural features. At doses ≥600 mg/day for more than a few months, ALA competitively inhibits biotin absorption and can induce functional biotin deficiency (Zempleni PMID 19348577). Biotin is required for four critical carboxylase enzymes in fatty acid, branched-chain amino acid, and odd-chain fatty acid metabolism, and deficiency symptoms include hair thinning, brittle nails, dermatitis, muscle pain, and in severe cases neurological effects. The solution is simple and cheap: add biotin 2-5 mg/day when taking chronic ALA ≥600 mg/day. Many commercial ALA products include biotin for this reason — check the label. Note that high-dose biotin can interfere with several laboratory immunoassays (thyroid function, cardiac troponin, hormone tests), so pause biotin for 48-72 hours before testing if your labs will be affected. For chronic ALA users not taking biotin, look for subtle signs of deficiency (hair and nail changes, skin issues) and add biotin empirically if they appear. ## Research Tools [ ### Peptide Calculator Reconstitution & syringe units ](/tools/reconstitution)[ ### Reconstitution Guide How to mix, step by step ](/guides/how-to-reconstitute-peptides)[ ### Nasal Spray Calc mL per actuation ](/tools/intranasal)[ ### Half-Life Visualizer Decay curves ](/tools/halflife) ## Related Compounds [View All](/wiki) [ ### Coenzyme Q10 Foundational Preclinical Coenzyme Q10 (CoQ10), also known as ubiquinone-10, ubidecarenone, or simply "coenzyme Q," is a lipid-soluble benzoquinone compound with a 50-carbon isoprenoid side chain (decaprenyl tail) that anchors it within the inner mitochondrial membrane. Preclinical View Profile ](/compound/coq10)[ ### Creatine Foundational Preclinical Creatine is the most-researched nutritional supplement in sports science and has emerged over the past decade as a cornerstone compound in the broader longevity conversation, extending beyond its traditional ergogenic applications into cognitive performance, brain health in aging, sarcopenia prevention, bone health, and recovery from traumatic brain injury. Preclinical View Profile ](/compound/creatine)[ ### Glycine Foundational Preclinical Glycine is the simplest amino acid—a single hydrogen atom replacing the typical side chain found in other proteinogenic amino acids—yet it performs an wide range of biological functions. Preclinical View Profile ](/compound/glycine)[ ### Magnesium Foundational Preclinical Magnesium is the fourth most abundant cation in the human body and the second most abundant intracellular cation after potassium, with approximately 25 grams present in a typical adult—roughly 60% stored in bone, 27% in muscle, 6-7% in other soft tissues, and less than 1% in extracellular fluid including serum. 1 studies View Profile ](/compound/magnesium)[ ### Omega-3 Fatty Acids Foundational Preclinical Omega-3 fatty acids represent one of the most thoroughly researched nutritional interventions of the past half-century, with thousands of clinical trials, dozens of major meta-analyses, regulatory approvals for specific pharmaceutical preparations, and foundational status in cardiovascular medicine, cognitive health, and inflammatory conditions. 12 studies View Profile ](/compound/omega-3-fatty-acids)[ ### Selenium Foundational Preclinical Selenium is an essential trace mineral first recognized as toxic in livestock grazing on seleniferous soils in the American West (reported by Kit Carson's expedition in the 1850s) and only later, in 1957, identified as essential for mammalian life when Klaus Schwarz discovered it prevented liver necrosis in rats deficient in the newly-described "Factor 3." The subsequent decades revealed that selenium's essentiality derives from its incorporation into approximately 25 distinct selenoproteins in humans, where it appears as the 21st genetically-encoded amino acid selenocysteine (Sec, U) at specific active sites. 20 studies View Profile ](/compound/selenium) ## Side-by-Side Comparisons [All Comparisons](/compare) Compare Alpha-Lipoic Acid head-to-head: mechanism, half-life, dosing, safety, and live pricing. [Alpha-Lipoic Acid vs Glutathione](/compare/alpha-lipoic-acid-vs-glutathione "Alpha Lipoic Acid vs Glutathione") Free 2026 Peptide Cheat Sheet — 50 pages, PDF Reconstitution math, concentration charts, half-lives, and vendor trust tiers. The reference we wish we had on day one. [Download Free](/guides/peptide-cheat-sheet-download?utm_source=compound-alpha-lipoic-acid) ### Need bloodwork before starting? Full hormone + metabolic panels from Anabolic Insights. Code CHONCH for first-order discount. [Order Bloodwork](https://anabolicinsights.ai/?ref=nwm2zjb) ![BodyHackGuide](/assets/bodyhackguide-logo-DOzZNUyh.webp) ### BodyHackGuide Your biohacking research hub — compound pricing, brain health protocols, dosing tools, and vendor reviews. [support@bodyhackguide.co](mailto:support@bodyhackguide.co) [](https://discord.gg/Mhq5UdRYBA)[](https://reddit.com/r/BodyHackGuide)[](https://x.com/bodyhackguide) Explore #### Explore - [Compare prices](/compare) - [Research suppliers](/vendors) - [Deals](/deals) - [Coupons](/coupons) - [Nootropics](/nootropics) - [Brain health](/brain-health) - [Blog](/blog) - [Guides](/guides) Tools #### Tools - [Reconstitution](/tools/reconstitution) - [Dosage calculator](/tools/dosage) - [Half-life visualizer](/tools/halflife) - [COA lookup](/tools/coa) - [Cost calculator](/tools/cost-calculator) - [Stack builder](/stack-builder) - [All tools →](/tools) Trust & vendors #### Trust & vendors - [Vendor directory](/vendors) - [Trust scorecard](/vendors/scorecard) - [Get BHG verified](/vendors/get-vetted) - [Scoring methodology](/vendors/methodology) - [Peptide cheatsheet](/guides/peptide-cheat-sheet-download) Company #### Company - [About](/about) - [Affiliate disclosure](/affiliate-disclosure) - [Editorial standards](/editorial-standards) - [Creators](/creators) - [Coaches](/coaches) - [Privacy](/privacy) - [Terms](/terms) - [Full site directory →](/site-directory) **Ownership & Affiliate Disclosure:** BodyHackGuide and BHG Labs share common ownership. We rank every vendor on the same public, reproducible [methodology](/vendors/methodology), and we earn a commission from purchases made through our links at no extra cost to you. Full details in our [affiliate disclosure](/affiliate-disclosure). **Research Disclaimer:** All compounds listed are for laboratory and research purposes only. Not for human consumption. This site does not sell, distribute, or promote any products. Always consult a qualified healthcare professional and comply with local regulations. © 2026 BodyHackGuide. All rights reserved. · [Terms](/terms) · [Privacy](/privacy) hi 👋